What exactly is Carpisetin/Tsuankode and what is it used for?

Capivasertib is an oral small molecule targeted drug approved in recent years. Its main mechanism of action is to inhibit the AKT signaling pathway. AKT is one of the core proteins of the intracellular PI3K/AKT/mTOR signaling axis. This pathway plays an important role in the occurrence, development and drug resistance of various malignant tumors. By activating this pathway, tumor cells can enhance their proliferation ability and resist apoptotic signals. Therefore, targeted inhibition of AKT is considered an important direction to break through the limitations of traditional treatments. As a selective AKT inhibitor, carpisetin inhibits tumor growth by blocking signal transduction and interfering with tumor cell metabolism and survival.

In terms of clinical application, the most important use of carpisetin is in the treatment of breast cancer, especially for patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Usually, such patients will still progress after receiving endocrine therapy and CDK4/6 inhibitors. However, the combination of capicipositi and fulvestrant and other drugs has shown significant disease control advantages in clinical studies. Overseas guidelines have gradually included it in recommended regimens, bringing new treatment opportunities to patients who previously lacked effective means.

Furthermore, the use of carpisetin is not limited to breast cancer. Since thePI3K/AKT/mTOR pathway is also highly activated in prostate cancer, ovarian cancer and some solid tumors, researchers are exploring its potential value in a variety of tumors. This broad-spectrum indication prospect makes it possible for carpisetin to expand into the treatment of more tumor types in the future.

To sum up, carpisetin is an innovative drug targetingAKT. It has shown clinical value in breast cancer and has shown application potential in a variety of solid tumors. It not only represents an important step for AKT inhibitors to successfully enter clinical practice, but also opens up a new direction for tumor treatment in the era of precision medicine.

Reference materials:https://www.drugs.com/mtm/capivasertib.html